Synlogic, Inc. (NASDAQ:SYBX) is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.47 per share.
Looking ahead, the full year loss are expected at $ 1.84 per share on the revenues of $ 0.98 million.
Previous Quarter Performance
Synlogic, Inc. unfold loss for the second quarter of $ 0.44 per share, from the revenue of $ 0.44 million. The quarterly revenues boosted 25.71 percent compared with the same quarter last year. Street analysts expected Synlogic, Inc. to report loss of $ 0.46 per share on revenue of $ 0.25 million for the second quarter. The bottom line results beat street analysts by $ 0.02 or 4.35 percent, at the same time, top line results outshined analysts by $ 0.19 million or 76.00 percent.
Stock Performance
Shares of Synlogic, Inc. traded up $ 0.02 or 1.08 percent on Wednesday, reaching $ 1.88 with volume of 86.60 thousand shares. Synlogic, Inc. has traded high as $ 1.90 and has cracked $ 1.81 on the downward trend
The closing price of $ 1.88, representing a 37.78 % increase from the 52 week low of $ 1.35 and a 46.24 % decrease over the 52 week high of $ 3.46.
The company has a market capital of $ 64.23 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Synlogic, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.synlogictx.com
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
